Minerva Neurosciences Inc. Stock

Description Minerva Neurosciences

Minerva Neurosciences Inc. (Symbol: NERV) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients suffering from central nervous system (CNS) disorders. The company was founded in 2013 and is headquartered in Waltham, Massachusetts, USA.

Minerva Neurosciences' primary goal is to design and develop groundbreaking therapies that target the unmet medical needs of those affected by mental health conditions, such as mood disorders, schizophrenia, and Parkinson's disease. By leveraging advances in neuroscience understanding and proprietary research findings, the company aims to create a new generation of treatment options that significantly reduce the burden of mental illness on patients, caregivers, and society as a whole.

The company's pipeline of product candidates includes several drugs at different stages of development:

1. Roluperidone (MIN-101): Roluperidone is a small molecule in Phase 3 clinical development for the treatment of negative symptoms in patients with schizophrenia. It is believed to work as an antagonist through a combination of serotonin (5-HT2A) and sigma-2 receptors, thus potentially reducing the negative symptoms associated with schizophrenia.

2. Seltorexant (MIN-202): This investigational drug, developed in collaboration with Janssen Pharmaceutica, is designed to treat patients with insomnia and major depressive disorder (MDD). Seltorexant is an orexin-2 receptor antagonist, which aims to promote sleep by inhibiting the orexin neurochemical system.

3. MIN-117: MIN-117 is a small molecule designed for the treatment of MDD with concurrent anxiety. It is designed to act as an antagonist on certain serotonin receptor subtypes (5-HT1A and 5-HT2A) and the sigma-1 receptor.

4. MIN-301: As a potential treatment for Parkinson's disease, MIN-301 is a novel biological entity that is intended to prevent or reduce the degeneration of dopaminergic neurons in the substantia nigra region of the brain which causes motor function deterioration in Parkinson's patients.

As a publicly-traded company listed on the Nasdaq Stock Market (Symbol: NERV), Minerva Neurosciences is committed to providing value to its shareholders by advancing its product candidates through clinical trials and ultimately obtaining regulatory approval for commercialization. However, investing in clinical-stage biopharmaceutical companies involves significant risks, as the success of the company's drugs depends on the outcome of clinical trials and regulatory actions, which are inherently uncertain.